Partial volume correction in longitudinal tau PET studies: is it really needed? by Alejandro Costoya-Sánchez, Alexis Moscoso, Tomás Sobrino, Álvaro Ruibal, Michel J. Grothe, Michael Schöll, Jesús Silva-Rodríguez, Pablo Aguiar

“…Methods: A cohort of 247 individuals from the Alzheimer's Disease Neuroimaging Initiative with concurrent baseline FTP-PET, amyloid-beta (Aβ) PET and structural MRI, as well as with follow-up FTP-PET and MRI were included in the study. …”
Get full text

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease by Nicholas J. Ashton, Andréa L. Benedet, Tharick A. Pascoal, Thomas K. Karikari, Juan Lantero-Rodriguez, Wagner S. Brum, Sulantha Mathotaarachchi, Joseph Therriault, Melissa Savard, Mira Chamoun, Erik Stoops, Cindy Francois, Eugeen Vanmechelen, Serge Gauthier, Eduardo R. Zimmer, Henrik Zetterberg, Kaj Blennow, Pedro Rosa-Neto

“…However, it is unknown if these increases transpire earlier, prior to amyloid-beta (Aβ) positivity as determined by position emission tomography (PET), and if an ordinal sequence of p-tau epitopes occurs at this incipient phase Methods: We measured CSF concentrations of p-tau181, p-tau217 and p-tau231 in 171 participants across the AD continuum who had undergone Aβ ([18F]AZD4694) and tau ([18F]MK6240) position emission tomography (PET) and clinical assessment Findings: All CSF p-tau biomarkers were accurate predictors of cognitive impairment but CSF p-tau217 demonstrated the largest fold-changes in AD patients in comparison to non-AD dementias and cognitively unimpaired individuals. …”
Get full text

Genetic and polygenic risk score analysis for Alzheimer's disease in the Chinese population by Xiaopu Zhou, Yu Chen, Fanny C. F. Ip, Nicole C. H. Lai, Yolanda Y. T. Li, Yuanbing Jiang, Huan Zhong, Yuewen Chen, Yulin Zhang, Shuangshuang Ma, Ronnie M. N. Lo, Kit Cheung, Estella P. S. Tong, Ho Ko, Maryam Shoai, Kin Y. Mok, John Hardy, Vincent C. T. Mok, Timothy C. Y. Kwok, Amy K. Y. Fu, Nancy Y. Ip

“…TREM2 H157Y might influence the amyloid beta 42/40 ratio and levels of immune‐associated proteins in plasma. …”
Get full text

Cerebral Microbleeds, Cerebrospinal Fluid, and Neuroimaging Markers in Clinical Subtypes of Alzheimer's Disease by Masaki Ikeda, Masaki Ikeda, Masaki Ikeda, Sayaka Kodaira, Hiroo Kasahara, Eriko Takai, Kazuaki Nagashima, Yukio Fujita, Kouki Makioka, Kimitoshi Hirayanagi, Natsumi Furuta, Minori Furuta, Etsuko Sanada, Ayumi Kobayashi, Yasuo Harigaya, Shun Nagamine, Noriaki Hattori, Yuichi Tashiro, Kazuhiro Kishi, Hirotaka Shimada, Takayuki Suto, Hisashi Tanaka, Yasujiro Sakai, Tsuneo Yamazaki, Yukiko Tanaka, Yuko Aihara, Masakuni Amari, Haruyasu Yamaguchi, Haruyasu Yamaguchi, Koichi Okamoto, Masamitsu Takatama, Kenji Ishii, Tetsuya Higuchi, Yoshito Tsushima, Yoshio Ikeda

“…Lobar cerebral microbleeds (CMBs) in Alzheimer's disease (AD) are associated with cerebral amyloid angiopathy (CAA) due to vascular amyloid beta (Aβ) deposits. However, the relationship between lobar CMBs and clinical subtypes of AD remains unknown. …”
Get full text

Comprehensive metabolomics and lipidomics profiling uncovering neuroprotective effects of Ginkgo biloba L. leaf extract on Alzheimer’s disease by Li-Wei Liu, Li-Wei Liu, Li-Wei Liu, He-Ying Yue, He-Ying Yue, He-Ying Yue, Jing Zou, Jing Zou, Jing Zou, Meng Tang, Fan-Mei Zou, Fan-Mei Zou, Fan-Mei Zou, Zhuo-Lun Li, Zhuo-Lun Li, Zhuo-Lun Li, Qing-Quan Jia, Qing-Quan Jia, Qing-Quan Jia, Yu-Bo Li, Jian Kang, Jian Kang, Jian Kang, Li-Hua Zuo, Li-Hua Zuo, Li-Hua Zuo

“…The Morris water maze test and immunohistochemistry were applied to evaluate the efficacy of GBLE.Results: As a result, administration of GBLE significantly improved the cognitive function and alleviated amyloid beta (Aβ) deposition in APP/PS1 mice, showing similar effects to donepezil. …”
Get full text

Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences by Elizabeth E. Moore, Dandan Liu, Kimberly R. Pechman, Lealani Mae Y. Acosta, Susan P. Bell, Susan P. Bell, L. Taylor Davis, L. Taylor Davis, Kaj Blennow, Kaj Blennow, Henrik Zetterberg, Henrik Zetterberg, Henrik Zetterberg, Henrik Zetterberg, Bennett A. Landman, Bennett A. Landman, Bennett A. Landman, Matthew S. Schrag, Timothy J. Hohman, Timothy J. Hohman, Katherine A. Gifford, Angela L. Jefferson, Angela L. Jefferson

“…Ordinary least square regressions examined cross-sectional associations between MCI severity and apolipoprotein E (APOE)-ε4 status, CSF biomarkers of amyloid beta (Aβ), phosphorylated tau, total tau, and synaptic dysfunction (neurogranin), baseline neuroimaging biomarkers, and baseline neuropsychological performance. …”
Get full text

Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects by Lih-Fen Lue, Ming-Chyi Pai, Ta-Fu Chen, Chaur-Jong Hu, Chaur-Jong Hu, Li-Kai Huang, Li-Kai Huang, Wei-Che Lin, Chau-Chung Wu, Jian-Shing Jeng, Kaj Blennow, Kaj Blennow, Marwan N. Sabbagh, Sui-Hing Yan, Pei-Ning Wang, Pei-Ning Wang, Shieh-Yueh Yang, Shieh-Yueh Yang, Hiroyuki Hatsuta, Hiroyuki Hatsuta, Satoru Morimoto, Satoru Morimoto, Akitoshi Takeda, Yoshiaki Itoh, Jun Liu, Haiqun Xie, Ming-Jang Chiu

“…However, the constituents of these hallmarks, amyloid beta (Aβ) 40, Aβ42, and total Tau (t-Tau), have been detected in the blood of cognitively normal subjects by using an immunomagnetic reduction (IMR) assay. …”
Get full text

Practice Effects in Mild Cognitive Impairment Increase Reversion Rates and Delay Detection of New Impairments by Mark Sanderson-Cimino, Mark Sanderson-Cimino, Jeremy A. Elman, Jeremy A. Elman, Xin M. Tu, Xin M. Tu, Xin M. Tu, Alden L. Gross, Matthew S. Panizzon, Matthew S. Panizzon, Daniel E. Gustavson, Mark W. Bondi, Mark W. Bondi, Emily C. Edmonds, Emily C. Edmonds, Joel S. Eppig, Carol E. Franz, Carol E. Franz, Amy J. Jak, Amy J. Jak, Michael J. Lyons, Kelsey R. Thomas, Kelsey R. Thomas, McKenna E. Williams, McKenna E. Williams, William S. Kremen, William S. Kremen, William S. Kremen

“…Biomarkers included cerebrospinal fluid phosphorylated tau and amyloid beta. Cox proportional models predicted time until first dementia diagnosis using PE-unadjusted and PE-adjusted diagnoses.ResultsAccounting for PEs increased MCI prevalence at follow-up by 9.2% (272 vs. 249 MCI), and reduced reversion to normal by 28.8% (57 vs. 80 reverters). …”
Get full text

Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology by Frances M. Potjewyd, Joel K. Annor‐Gyamfi, Jeffrey Aubé, Shaoyou Chu, Ivie L. Conlon, Kevin J. Frankowski, Shiva K. R. Guduru, Brian P. Hardy, Megan D. Hopkins, Chizuru Kinoshita, Dmitri B. Kireev, Emily R. Mason, Charles T. Moerk, Felix Nwogbo, Kenneth H. Pearce Jr., Timothy I. Richardson, David A. Rogers, Disha M. Soni, Michael Stashko, Xiaodong Wang, Carrow Wells, Timothy M. Willson, Stephen V. Frye, Jessica E. Young, Alison D. Axtman

“…Nine compounds targeting proteins expressed by six AD‐implicated genes prioritized for study by Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT‐AD) teams were selected for G‐protein coupled receptor (GPCR), amyloid beta (Aβ) and tau, and pharmacokinetic (PK) studies. …”
Get full text

Lumbar puncture increases Alzheimer’s disease biomarker levels in cerebrospinal fluid of rhesus monkeys by Jianglei Xu, Hao Li, Yingzhou Hu, Shihao Wu, Liping Wu, Xiaoguang Lei, Longbao Lv, Yi Lu, Jing Wu, Juanjuan Li, Bingyin Shi, Jiali Li, Christoph W. Turck, Wenchao Wang, Xintian Hu

“…To determine the effects of LP on CSF AD biomarkers, we collected CSF samples at seven different time points after an LP in rhesus monkeys. We find that amyloid-beta (Aβ) and Tau levels increased significantly on day 1, peaked on day 3, and returned to baseline on day 10 after LP. …”
Get full text

Anti-LINGO-1 antibody ameliorates cognitive impairment, promotes adult hippocampal neurogenesis, and increases the abundance of CB1R-rich CCK-GABAergic interneurons in AD mice by Qi He, Lin Jiang, Yi Zhang, Hao Yang, Chun-Ni Zhou, Yu-Han Xie, Yan-Min Luo, Shan-Shan Zhang, Lin Zhu, Yi-Jing Guo, Yu-Hui Deng, Xin Liang, Qian Xiao, Lei Zhang, Jing Tang, Du-Juan Huang, Yu-Ning Zhou, Xiao-Yun Dou, Feng-Lei Chao, Yong Tang

“…Behavioral, stereology, immunohistochemistry and immunofluorescence analyses revealed that the anti-LINGO-1 antibody significantly improved the cognitive abilities, promoted adult hippocampal neurogenesis (AHN), decreased the amyloid beta (Aβ) deposition, enlarged the hippocampal volume, and increased the numbers of total neurons and GABAergic interneurons, including GABAergic and CCK-GABAergic interneurons rich in cannabinoid type 1 receptor (CB1R), in the hippocampus of AD mice. …”
Get full text

Protective Alzheimer's disease-associated APP A673T variant predominantly decreases sAPPβ levels in cerebrospinal fluid and 2D/3D cell culture models by Rebekka Wittrahm, Mari Takalo, Teemu Kuulasmaa, Petra M. Mäkinen, Petri Mäkinen, Saša Končarević, Vadim Fartzdinov, Stefan Selzer, Tarja Kokkola, Leila Antikainen, Henna Martiskainen, Susanna Kemppainen, Mikael Marttinen, Heli Jeskanen, Hannah Rostalski, Eija Rahunen, Miia Kivipelto, Tiia Ngandu, Teemu Natunen, Jean-Charles Lambert, Rudolph E. Tanzi, Doo Yeon Kim, Tuomas Rauramaa, Sanna-Kaisa Herukka, Hilkka Soininen, Markku Laakso, Ian Pike, Ville Leinonen, Annakaisa Haapasalo, Mikko Hiltunen

“…Thereafter, different studies have discovered that the carriers of the APP A673T variant show reduced levels of amyloid beta (Aβ) in the plasma and better cognitive performance at high age. …”
Get full text

Moderate intrinsic phenotypic alterations in C9orf72 ALS/FTD iPSC-microglia despite the presence of C9orf72 pathological features by Ileana Lorenzini, Eric Alsop, Jennifer Levy, Lauren M. Gittings, Deepti Lall, Benjamin E. Rabichow, Stephen Moore, Stephen Moore, Ryan Pevey, Ryan Pevey, Lynette M. Bustos, Lynette M. Bustos, Camelia Burciu, Divya Bhatia, Mo Singer, Justin Saul, Amanda McQuade, Amanda McQuade, Amanda McQuade, Makis Tzioras, Makis Tzioras, Thomas A. Mota, Amber Logemann, Jamie Rose, Jamie Rose, Sandra Almeida, Fen-Biao Gao, Michael Marks, Christopher J. Donnelly, Elizabeth Hutchins, Shu-Ting Hung, Justin Ichida, Robert Bowser, Tara Spires-Jones, Tara Spires-Jones, Mathew Blurton-Jones, Mathew Blurton-Jones, Mathew Blurton-Jones, Tania F. Gendron, Tania F. Gendron, Robert H. Baloh, Robert H. Baloh, Kendall Van Keuren-Jensen, Rita Sattler

“…Healthy control and C9orf72 ALS/FTD iPSC-MG equally express microglial specific genes and perform microglial functions, including inflammatory cytokine release and phagocytosis of extracellular cargos, such as synthetic amyloid beta peptides and healthy human brain synaptoneurosomes. …”
Get full text

Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease by Muhammad Ali, Derek B. Archer, Priyanka Gorijala, Daniel Western, Jigyasha Timsina, Maria V. Fernández, Ting-Chen Wang, Claudia L. Satizabal, Qiong Yang, Alexa S. Beiser, Ruiqi Wang, Gengsheng Chen, Brian Gordon, Tammie L. S. Benzinger, Chengjie Xiong, John C. Morris, Randall J. Bateman, Celeste M. Karch, Eric McDade, Alison Goate, Sudha Seshadri, Richard P. Mayeux, Reisa A. Sperling, Rachel F. Buckley, Keith A. Johnson, Hong-Hee Won, Sang-Hyuk Jung, Hang-Rai Kim, Sang Won Seo, Hee Jin Kim, Elizabeth Mormino, Simon M. Laws, Kang-Hsien Fan, M. Ilyas Kamboh, Prashanthi Vemuri, Vijay K. Ramanan, Hyun-Sik Yang, Allen Wenzel, Hema Sekhar Reddy Rajula, Aniket Mishra, Carole Dufouil, Stephanie Debette, Oscar L. Lopez, Steven T. DeKosky, Feifei Tao, Michael W. Nagle, Knight Alzheimer Disease Research Center (Knight ADRC), the Dominantly Inherited Alzheimer Network (DIAN), Alzheimer’s Disease Neuroimaging Initiative (ADNI), ADNI-DOD, A4 Study Team, the Australian Imaging Biomarkers, Lifestyle (AIBL) Study, Timothy J. Hohman, Yun Ju Sung, Logan Dumitrescu, Carlos Cruchaga

“…Abstract Amyloid PET imaging has been crucial for detecting the accumulation of amyloid beta (Aβ) deposits in the brain and to study Alzheimer’s disease (AD). …”
Get full text

Neuropathological and transcriptomic characteristics of the aged brain by Jeremy A Miller, Angela Guillozet-Bongaarts, Laura E Gibbons, Nadia Postupna, Anne Renz, Allison E Beller, Susan M Sunkin, Lydia Ng, Shannon E Rose, Kimberly A Smith, Aaron Szafer, Chris Barber, Darren Bertagnolli, Kristopher Bickley, Krissy Brouner, Shiella Caldejon, Mike Chapin, Mindy L Chua, Natalie M Coleman, Eiron Cudaback, Christine Cuhaciyan, Rachel A Dalley, Nick Dee, Tsega Desta, Tim A Dolbeare, Nadezhda I Dotson, Michael Fisher, Nathalie Gaudreault, Garrett Gee, Terri L Gilbert, Jeff Goldy, Fiona Griffin, Caroline Habel, Zeb Haradon, Nika Hejazinia, Leanne L Hellstern, Steve Horvath, Kim Howard, Robert Howard, Justin Johal, Nikolas L Jorstad, Samuel R Josephsen, Chihchau L Kuan, Florence Lai, Eric Lee, Felix Lee, Tracy Lemon, Xianwu Li, Desiree A Marshall, Jose Melchor, Shubhabrata Mukherjee, Julie Nyhus, Julie Pendergraft, Lydia Potekhina, Elizabeth Y Rha, Samantha Rice, David Rosen, Abharika Sapru, Aimee Schantz, Elaine Shen, Emily Sherfield, Shu Shi, Andy J Sodt, Nivretta Thatra, Michael Tieu, Angela M Wilson, Thomas J Montine, Eric B Larson, Amy Bernard, Paul K Crane, Richard G Ellenbogen, C Dirk Keene, Ed Lein

“…Treatments targeting specific pathologies such as amyloid beta in Alzheimer’s disease (AD) have not led to effective treatments, and there is increasing evidence of a disconnect between traditional pathology and cognitive abilities with advancing age, indicative of individual variation in resilience to pathology. …”
Get full text

Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI) by Itziar de Rojas, J. Romero, O. Rodríguez-Gomez, P. Pesini, A. Sanabria, A. Pérez-Cordon, C. Abdelnour, I. Hernández, M. Rosende-Roca, A. Mauleón, L. Vargas, M. Alegret, A. Espinosa, G. Ortega, S. Gil, M. Guitart, A. Gailhajanet, M. A. Santos-Santos, Sonia Moreno-Grau, O. Sotolongo-Grau, S. Ruiz, L. Montrreal, E. Martín, E. Pelejà, F. Lomeña, F. Campos, A. Vivas, M. Gómez-Chiari, M. A. Tejero, J. Giménez, V. Pérez-Grijalba, G. M. Marquié, G. Monté-Rubio, S. Valero, A. Orellana, L. Tárraga, M. Sarasa, A. Ruiz, M. Boada, on behalf of the FACEHBI study

“…Abstract Background Peripheral biomarkers that identify individuals at risk of developing Alzheimer’s disease (AD) or predicting high amyloid beta (Aβ) brain burden would be highly valuable. …”
Get full text

Brain-IT: Targeting the brain using information technology for secondary prevention of mild neurocognitive disorder by Patrick Manser, Eling D. de Bruin

“…Modulating heart rate oscillation affects plasma amyloid beta and tau levels in younger and older adults. …”
Get full text

Mechanical energy transfer and dissipation in fibrous beta-sheet-rich proteins by Xu, Zhiping, Buehler, Markus J

“…By investigating four model proteins including two morphologies of amyloids, beta solenoids, and silk beta-sheet nanocrystals, we find that all beta-sheet-rich protein fibrils provide outstanding elastic moduli, where the silk nanocrystal reaches the highest value of ≈40 GPa. …”
Get full text
Get full text

MPTAC Determines APP Fragmentation via Sensing Sulfur Amino Acid Catabolism by Tamaki Suganuma, Selene K. Swanson, Madelaine Gogol, Timothy J. Garrett, Juliana Conkright-Fincham, Laurence Florens, Michael P. Washburn, Jerry L. Workman

“…Keywords: MPTAC, sulfur amino acid catabolism, APP fragmentation, SAMe, PRMT5, MPT synthase, fatty acid beta-oxidation, amyloid beta…”
Get full text